WF
LCTX icon

WoodTrust Financial’s Lineage Cell Therapeutics LCTX Stock Holding History

WoodTrust Financial’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Hold
10,000
– – ﹤0.01% 178
2026
Q1 		$16K Hold
10,000
– – ﹤0.01% 173
2025
Q4 		$17K Buy
+10,000
New +$17.3K ﹤0.01% 179

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

WoodTrust Financial's LCTX Position: Q2 2026 in Review

WoodTrust Financial held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 10,000 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #178.

WoodTrust Financial first reported a position in LCTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $17K in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • WoodTrust Financial held 10,000 shares of Lineage Cell Therapeutics worth $13K as of Q2 2026.
  • WoodTrust Financial left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of WoodTrust Financial's portfolio in Q2 2026, its #178 holding.
  • WoodTrust Financial first reported a position in Lineage Cell Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • WoodTrust Financial's Lineage Cell Therapeutics position peaked at $17K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on WoodTrust Financial's 13F filing for Q2 2026, filed 27 Jul 2026.